These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37713027)

  • 1. Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan.
    Kotake K; Noritake Y; Kawakami Y
    Int J Clin Pharm; 2023 Oct; 45(5):1252-1259. PubMed ID: 37713027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
    Takahashi H; Kubono S; Taneyama T; Kuramoto K; Mizutani H; Tanaka N; Yoshida M
    Drugs R D; 2019 Mar; 19(1):47-55. PubMed ID: 30607819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of α
    Nagata Y; Kawahara T; Goto T; Inoue S; Teramoto Y; Jiang G; Fujimoto N; Miyamoto H
    Am J Cancer Res; 2020; 10(12):4386-4398. PubMed ID: 33415006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
    Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
    Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats.
    Sugaya K; Nishijima S; Miyazato M; Ashitomi K; Hatano T; Ogawa Y
    Neurosci Lett; 2002 Aug; 328(1):74-6. PubMed ID: 12123863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.
    Kwon SY; Lee KS; Yoo TK; Chung JI; Lee JY; Hong JH; Seo SI; Jung TY; Kwak C; Kang TW; Yun SJ
    Urology; 2018 Jan; 111():145-150. PubMed ID: 28624553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
    Kosugi S; Ikemoto I; Furuta A; Shimomura T; Kiyota H; Suzuki Y; Kishimoto K; Egaway S; Torii S; Shirai H; Takeuchi H; Abe K
    Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):691-9. PubMed ID: 17682448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin].
    Furuya R; Hisasue S; Ogura H; Furuya S; Masumori N; Itoh N; Tsukamoto T
    Hinyokika Kiyo; 2005 Nov; 51(11):763-6. PubMed ID: 16363711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia].
    Tomiyama Y; Tatemichi S; Tadachi M; Kobayashi S; Hayashi M; Kobayashi M; Yamazaki Y; Shibata N
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():225-30. PubMed ID: 16518087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.
    Tatemichi S; Tomiyama Y; Maruyama I; Kobayashi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N
    Neurourol Urodyn; 2006; 25(7):792-9; discussion 800-1. PubMed ID: 16894620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].
    Muramatsu I; Suzuki F; Tanaka T; Yamamoto H; Morishima S
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():187-98. PubMed ID: 16518082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New alpha blockers to treat male lower urinary tract symptoms.
    Hwang EC; Gandhi S; Jung JH
    Curr Opin Urol; 2018 May; 28(3):273-276. PubMed ID: 29613909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Urol Int; 2021; 105(9-10):817-825. PubMed ID: 33690238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.